State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Meningococcal type W most notable infectious disease in 2017 The report ‘State of Infectious Diseases in the Netherlands in 2017’ published by RIVM today, provides an overview of the most important developments in infectious diseases in the Netherlands and a
Large increase in legionellosis in the Netherlands The Municipal Public Health Services (GGD) received 561 reports of legionellosis over the past year. Never before has RIVM registered as many reports of this disease as in the past year.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
The National Immunisation Programme in the Netherlands 2013 - 2014 Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).
Increasing number of girls immunised against HPV In 2014 the number of girls who were immunised against the human papilloma virus (HPV) rose. This virus can cause cervical cancer later in life.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).